Replies to post #196704 on Biotech Values

[DewDiligence]

RVNC selling 3.74M* shares at unspecified price:

http://finance.yahoo.com/news/revance-therapeutics-announces-proposed-public-110200696.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

RVNC’s phase-3 trials for RT002 in glabellar lines will not have a Botox-comparator arm, (as the phase-2 BELMONT study did), according to CEO Dan Browne on today’s PJ webcast.

Rather, RVNC’s phase-3 program in glabellar lines will comprise: two identical trials randomized trials of RT002 (at 40U dose) vs placebo, and one open-label safety study lasting 12 months.